{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:07:32Z","timestamp":1793995652380,"version":"4.8.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RED2022-134287-T"],"award-info":[{"award-number":["RED2022-134287-T"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CPP2021-008597"],"award-info":[{"award-number":["CPP2021-008597"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00808"],"award-info":[{"award-number":["PI19\/00808"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023479","name":"CRIS Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011698","name":"Junta de Comunidades de Castilla-La Mancha","doi-asserted-by":"publisher","award":["SBPLY\/21\/180501\/000050"],"award-info":[{"award-number":["SBPLY\/21\/180501\/000050"]}],"id":[{"id":"10.13039\/501100011698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031557","name":"Diputaci\u00f3n de Albacete","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031557","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118352","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:19:59Z","timestamp":1752592799000},"page":"118352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Liposomal formulation of the CDK9 PROTAC THAL-SNS-032 enhances the antitumor activity in breast cancer cell lines"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-669X","authenticated-orcid":false,"given":"Mar\u00eda","family":"Arenas-Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-9688","authenticated-orcid":false,"given":"Mar\u00eda del Mar","family":"Noblejas-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Ripoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Moya-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"D\u00edaz-Tejeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Martin-Ezama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1589-5399","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alonso-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2025.118352_bib1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation, from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118352_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109574","article-title":"Inhibitors to degraders, changing paradigm in drug discovery","volume":"27","author":"Haridas","year":"2024","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.biopha.2025.118352_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118352_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jb\/mvad113","article-title":"Protein degraders - from thalidomide to new PROTACs","volume":"175","author":"Ito","year":"2024","journal-title":"J. Biochem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-022-01535-7","article-title":"Clinical considerations for the design of PROTACs in cancer","volume":"21","author":"Nieto-Jim\u00e9nez","year":"2022","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2025.118352_bib6","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.tips.2018.10.009","article-title":"Activating p53 and inhibiting superenhancers to cure leukemia","volume":"39","author":"Ball","year":"2018","journal-title":"Trends Pharm. Sci."},{"issue":"590","key":"10.1016\/j.biopha.2025.118352_bib7","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1126\/scisignal.aav7259","article-title":"Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer","volume":"12","author":"Blake","year":"2019","journal-title":"Sci. Signal"},{"key":"10.1016\/j.biopha.2025.118352_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109508","article-title":"CDK9 inhibitors reactivate p53 by downregulating iASPP","volume":"67","author":"Wu","year":"2020","journal-title":"Cell Signal"},{"issue":"2","key":"10.1016\/j.biopha.2025.118352_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2025.118352_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113091","article-title":"Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion","volume":"211","author":"Qiu","year":"2021","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118352_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128061","article-title":"Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax","volume":"43","author":"King","year":"2021","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"19","key":"10.1016\/j.biopha.2025.118352_bib12","doi-asserted-by":"crossref","first-page":"14822","DOI":"10.1021\/acs.jmedchem.1c01350","article-title":"Discovery of potent and selective CDK9 degraders for targeting transcription regulation in triple-negative breast cancer","volume":"64","author":"Wei","year":"2021","journal-title":"J. Med Chem."},{"issue":"10","key":"10.1016\/j.biopha.2025.118352_bib13","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.3390\/ijms23105476","article-title":"Antitumoral activity of a CDK9 PROTAC compound in HER2-positive breast cancer","volume":"23","author":"Noblejas-L\u00f3pez","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118352_bib14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1021\/acsmedchemlett.4c00165","article-title":"Transforming therapeutic approaches with PROTAC technology, new targets and potentials","volume":"15","author":"Kargbo","year":"2024","journal-title":"ACS Med Chem. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib15","first-page":"1","article-title":"An overview of PROTACs, a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed. 2022 31"},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118352_bib17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.biopha.2025.118352_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.805336","article-title":"Options to improve the action of PROTACs in cancer, development of controlled delivery nanoparticles","volume":"9","author":"Juan","year":"2022","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2025.118352_bib19","article-title":"Proteolysis-targeting drug delivery system (ProDDS), integrating targeted protein degradation concepts into formulation design","author":"Chen","year":"2024","journal-title":"Chem. Soc. Rev."},{"issue":"13","key":"10.1016\/j.biopha.2025.118352_bib20","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system, advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"10","key":"10.1016\/j.biopha.2025.118352_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12100986","article-title":"Controlled delivery of bet-protacs, In vitro evaluation of MZ1-loaded polymeric antibody conjugated nanoparticles in breast cancer","volume":"12","author":"Cimas","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118352_bib22","article-title":"Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles","volume":"16","author":"He","year":"2022","journal-title":"Mater. Today Bio"},{"issue":"10","key":"10.1016\/j.biopha.2025.118352_bib23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.tips.2020.08.008","article-title":"Nanoformulation of BRD4-degrading PROTAC, IMproving Druggability to Target the \u2018Undruggable\u2019 MYC in pancreatic cancer","volume":"41","author":"Minko","year":"2020","journal-title":"Trends Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib24","article-title":"Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118352_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.143883","article-title":"Tailoring albumin-based theranostic PROTACs nanoparticles for enhanced NIR-II bioimaging and synergistic cancer chemo-phototherapy","volume":"469","author":"Hu","year":"2023","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.biopha.2025.118352_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124973","article-title":"Liposomes-mediated enhanced antitumor effect of docetaxel with BRD4-PROTAC as synergist for breast cancer chemotherapy\/immunotherapy","volume":"668","author":"Chen","year":"2025","journal-title":"Int J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1186\/s12951-024-02967-7","article-title":"Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy","volume":"22","author":"Guan","year":"2024","journal-title":"J. Nanobiotechnol"},{"key":"10.1016\/j.biopha.2025.118352_bib28","article-title":"Towards principled design of cancer nanomedicine to accelerate clinical translation","volume":"13","author":"Souri","year":"2022","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.biopha.2025.118352_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101512","article-title":"Nanoparticle-based medicines in clinical cancer therapy","volume":"45","author":"Wang","year":"2022","journal-title":"Nano Today"},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib30","first-page":"1","article-title":"Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery","volume":"20","author":"Huang","year":"2022","journal-title":"J. Nanobiotechnol. 2022 201"},{"issue":"18","key":"10.1016\/j.biopha.2025.118352_bib31","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.3390\/cancers14184474","article-title":"Enhanced antitumoral activity of encapsulated BET inhibitors when combined with PARP inhibitors for the treatment of triple-negative breast and ovarian cancers","volume":"14","author":"Juan","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-01008-x","article-title":"Mithramycin delivery systems to develop effective therapies in sarcomas","volume":"19","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0939-6411(02)00130-3","article-title":"M\u00fcller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles \u2013 evaluation of the method and process parameters","volume":"55","author":"Schubert","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.biopha.2025.118352_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0939-6411(97)00150-1","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism","volume":"45","author":"Zur M\u00fchlen","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.biopha.2025.118352_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/08940886.2017.1338410","article-title":"MIRAS, the infrared synchrotron radiation beamline at ALBA","volume":"30","author":"Yousef","year":"2017","journal-title":"Synchrotron Radiat. N."},{"issue":"9","key":"10.1016\/j.biopha.2025.118352_bib36","first-page":"2300","article-title":"Quasar, easy machine learning for biospectroscopy","volume":"10","author":"Toplak","year":"2021","journal-title":"Cells 2021 Vol. 10 Page 2300"},{"key":"10.1016\/j.biopha.2025.118352_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117165","article-title":"Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation","volume":"178","author":"D\u00edaz-Tejeiro","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118352_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(02)00081-9","article-title":"Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization","volume":"239","author":"Hu","year":"2002","journal-title":"Int J. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2025.118352_bib39","first-page":"437","article-title":"Evaluation and comparison of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as vectors to develop hydrochlorothiazide effective and safe pediatric oral liquid formulations","volume":"13","author":"Mura","year":"2021","journal-title":"Pharm. 2021 Vol. 13 Page 437"},{"issue":"25","key":"10.1016\/j.biopha.2025.118352_bib40","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1039\/b819582j","article-title":"Characterising the phase behaviour of stearic acid and its triethanolamine soap and acid\u2013soap by infrared spectroscopy","volume":"11","author":"Pudney","year":"2009","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"30","key":"10.1016\/j.biopha.2025.118352_bib41","doi-asserted-by":"crossref","first-page":"42264","DOI":"10.1002\/app.42264","article-title":"Mechanical and rheological properties of polypropylene\/bentonite composites with stearic acid as an interface modifier","volume":"132","author":"Del Angel","year":"2015","journal-title":"J. Appl. Polym. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118352_bib42","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1021\/cm021222u","article-title":"Surface treatment of calcite with fatty acids, Structure and properties of the organic monolayer","volume":"14","author":"Osman","year":"2002","journal-title":"Chem. Mater."},{"issue":"6","key":"10.1016\/j.biopha.2025.118352_bib43","first-page":"765","article-title":"Diacerein-loaded hyaluosomes as a dual-function platform for osteoarthritis management via intra-articular injection, in vitro characterization and in vivo assessment in a rat model","volume":"13","author":"Eladawy","year":"2021","journal-title":"Pharm. 2021 Vol. 13 Page 765"},{"issue":"03","key":"10.1016\/j.biopha.2025.118352_bib44","first-page":"527","article-title":"ATR-FTIR based pre and post formulation compatibility studies for the design of niosomal drug delivery system containing nonionic amphiphiles and chondroprotective drug","volume":"37","author":"Khan","year":"2015","journal-title":"JChemSocPak"},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12645-023-00180-z","article-title":"Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancer","volume":"14","author":"Juan","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.biopha.2025.118352_bib46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s42452-024-05897-z","article-title":"Solid lipid nanocarriers for drug delivery, design innovations and characterization strategies-a comprehensive review","volume":"6","author":"Pawar","year":"2024","journal-title":"Discov. Appl. Sci."},{"issue":"45","key":"10.1016\/j.biopha.2025.118352_bib47","doi-asserted-by":"crossref","first-page":"26777","DOI":"10.1039\/D0RA03491F","article-title":"A brief review on solid lipid nanoparticles, part and parcel of contemporary drug delivery systems","volume":"10","author":"Duan","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.biopha.2025.118352_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1208\/s12249-021-02179-4","article-title":"Strategies for liposome drug delivery systems to improve tumor treatment efficacy","volume":"23","author":"Wang","year":"2022","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.biopha.2025.118352_bib49","first-page":"782","article-title":"Coating materials to increase the stability of liposomes","volume":"15","author":"Pasarin","year":"2023","journal-title":"Polym. 2023 Vol. 15 Page 782"},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/s12645-023-00169-8","article-title":"Doxorubicin-loaded liposomes surface engineered with the matrix metalloproteinase-2 cleavable polyethylene glycol conjugate for cancer therapy","volume":"14","author":"Askarizadeh","year":"2023","journal-title":"Cancer Nanotechnol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118352_bib51","first-page":"2102","article-title":"Pluronic F-68 and F-127 based nanomedicines for advancing combination cancer therapy","volume":"15","author":"Khaliq","year":"2023","journal-title":"Pharm. 2023 Vol. 15 Page 2102"},{"issue":"10","key":"10.1016\/j.biopha.2025.118352_bib52","first-page":"1988","article-title":"Vitamin E lipid-based nanodevices as a tool for ovine sperm protection against oxidative stress, impact on sperm motility","volume":"11","author":"Jurado-Campos","year":"2022","journal-title":"Antioxid. 2022 Vol. 11 Page 1988"},{"issue":"3","key":"10.1016\/j.biopha.2025.118352_bib53","first-page":"772","article-title":"Recent progress of lipid nanoparticles-based lipophilic drug delivery, focus on surface modifications","volume":"15","author":"Seo","year":"2023","journal-title":"Pharm. 2023 Vol. 15 Page 772"},{"key":"10.1016\/j.biopha.2025.118352_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1296091","article-title":"Lipid-based nanoparticles as drug delivery carriers for cancer therapy","volume":"14","author":"Waheed","year":"2024","journal-title":"Front Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2025.118352_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813820","article-title":"Guanylation reactions for the rational design of cancer therapeutic agents","volume":"24","author":"del Campo-Balguer\u00edas","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118352_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jcis.2024.06.157","article-title":"Fluorescence lifetime nanothermometer based on the equilibrium formation of anthracene AIE-excimers in living cells","volume":"674","author":"Ripoll","year":"2024","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.biopha.2025.118352_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.118352_bib58","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs, current and future potential as a precision medicine strategy to combat cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118352_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2014 a new approach to cancer therapy","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib60","first-page":"1","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Molecular Cancer 2024 231"},{"issue":"1","key":"10.1016\/j.biopha.2025.118352_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2219470","article-title":"Targeting CDK9 with selective inhibitors or degraders in tumor therapy, an overview of recent developments","volume":"24","author":"Xiao","year":"2023","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2025.118352_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114792","article-title":"Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC)","volume":"243","author":"\u0158ezn\u00ed\u010dkov\u00e1","year":"2022","journal-title":"Eur. J. Med Chem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118352_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic, An update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med"},{"issue":"2","key":"10.1016\/j.biopha.2025.118352_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/acs.bioconjchem.8b00732","article-title":"The endosomal escape of nanoparticles, toward more efficient cellular delivery","volume":"30","author":"Smith","year":"2019","journal-title":"Bioconjug Chem."},{"issue":"11","key":"10.1016\/j.biopha.2025.118352_bib65","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape, A bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118352_bib66","unstructured":"Alonso-Moreno C.. Created in BioRender. doi:\u3008https:\/\/BioRender.com\/w11s089\u3009."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:49:32Z","timestamp":1777574972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225005463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":66,"alternative-id":["S0753332225005463"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118352","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal formulation of the CDK9 PROTAC THAL-SNS-032 enhances the antitumor activity in breast cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118352"}}